NK/T-cell lymphoma

A nasal lesion that bleeds, obstructs breathing or fails to heal can resemble infection or inflammation. Obtain viable tissue for expert hematopathology; extensive necrosis can make a superficial specimen inconclusive. The report should integrate morphology, a cytotoxic NK/T-cell immunophenotype and EBER testing in tumor tissue.

The disease can arise outside the nose, including skin or the gastrointestinal tract. Its name does not imply confinement to the nose. A blood EBV result alone cannot diagnose it; EBV-positive nodal T/NK lymphoma and aggressive NK-cell leukemia require separate classification.

Assessment usually combines PET/CT, local examination and imaging, blood counts, LDH, liver and kidney function, and quantitative plasma EBV DNA. Bone marrow or other site evaluation is selected to clarify suspected involvement. Record the laboratory and specimen type so serial viral measurements are interpretable.

PINK/PINK-E estimates and treatment response help frame risk; neither supplies a personal survival deadline. Symptoms, nutrition, infections and the ability to tolerate asparaginase-containing therapy also influence the plan.

For localized nasal disease, radiotherapy is a central potentially curative treatment. Many patients receive combined treatment with non-anthracycline systemic therapy; selected low-risk or less-fit patients may receive radiation alone. Concurrent, sequential and sandwich schedules are specific strategies rather than interchangeable appointments.

A randomized early-stage study supports combining DDGP and radiation in its studied population, but its size and baseline imbalance limit universal conclusions. Radiation target coverage, timing and normal-tissue protection need specialist planning; a good initial chemotherapy response is not by itself permission to omit radiation.

Asparaginase or pegaspargase-containing combinations are important systemic options. Examples include P-GEMOX, modified SMILE and DDGP; the center selects a program according to disease extent, fitness and experience. Conventional CHOP-type therapy alone should not be assumed to work as it does in other lymphomas.

SPIRIT studied sintilimab plus P-GEMOX in newly diagnosed advanced disease and reported encouraging activity. It was a single-arm phase II study, so it does not establish superiority over every asparaginase regimen or justify adding immunotherapy to all patients.

At relapse, reassess pathology when feasible, distribution, prior radiation fields and response to asparaginase. Sugemalimab is approved in China for relapsed or refractory extranodal NK/T-cell lymphoma; GEMSTONE-201 was a single-arm phase II study. Its responses do not establish a guaranteed cure or a first-line indication.

A 2026 phase Ib/II study of liposomal mitoxantrone plus tislelizumab adds a combination research option, with toxicity and patient selection still important. For any checkpoint inhibitor, verify the actual disease indication, treatment line and country; lung-cancer approval of the same medicine does not authorize this use.

Allogeneic transplantation may be discussed for selected patients with advanced or relapsed disease that is controlled sufficiently for transplant. Potential durable control is balanced against infection, graft-versus-host disease and treatment-related mortality. It is not a routine addition for every localized case in complete remission.

Recent transplant reports remain largely retrospective and subject to selection effects. Trials are also evaluating upfront immune combinations, including randomized SPIRIT-02. Trial registration indicates a research question, not a positive result or assured enrollment.

Response assessment combines symptoms, examination, imaging and serial plasma EBV DNA. Persistent or rising EBV DNA warrants interpretation alongside the rest of the assessment; an undetectable result does not independently prove cure. New PET uptake may need confirmation if infection or inflammation is plausible.

Asparaginase-containing therapy needs monitoring for liver injury, pancreatitis, glucose disturbance, allergy and clotting or bleeding complications. Fever with low blood counts, significant bleeding, severe abdominal pain, breathlessness or confusion requires urgent assessment. Persistent fever with falling counts or organ dysfunction also raises concern for infection or lymphoma-associated hyperinflammation.

Bring the pathology report and tissue availability, EBER and immunophenotype results, baseline and latest PET/CT, local radiation plans, EBV DNA trends, and a dated treatment and toxicity history. Ask which decisions depend on disease site, which therapy is locally approved, and how response will change the next step.